Semaglutide vs Tirzepatide: How the Two Weight Programs Differ

Semaglutide and tirzepatide are both weekly injections that reduce appetite and help with long-term weight management, but they work on different hormone targets. Semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GIP and GLP-1 receptors. In a 2025 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide, though the right choice for you depends on your health history, how you tolerate the medication and what your provider recommends.

How each medication works

Your gut releases hormones after you eat. Two of them, GLP-1 and GIP, help signal fullness, slow how quickly the stomach empties and support blood sugar control.

Semaglutide copies the action of GLP-1. It helps you feel full sooner and stay satisfied longer.

Tirzepatide is a single molecule that activates both GIP and GLP-1 receptors. Researchers believe the added GIP action is part of why it produced larger average weight reduction in clinical trials, although the exact reasons are still being studied.

Neither medication replaces training, sleep and good nutrition. Both brand labels state they are meant to be used with a reduced-calorie diet and increased physical activity. That fits the way RULE members already live: the medication helps with appetite, and your habits do the long-term work.

Side-by-side comparison

What the head-to-head trial found

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared brand tirzepatide with brand semaglutide in adults with obesity who did not have type 2 diabetes. Participants on tirzepatide had greater average reductions in body weight and waist size than those on semaglutide. Digestive side effects were common in both groups.

Two points matter here. First, trial averages describe groups, not individuals. Some people respond strongly to semaglutide, and some people tolerate one medication better than the other. Second, the trial used FDA-approved brand products. Compounded versions have not been studied in trials like this one.

Side effects and safety

The two labels list very similar warnings. The most common effects are digestive and tend to ease as your body adjusts. Your provider increases the dose gradually to help with this.

Both labels also include serious warnings your provider screens for before prescribing:

• Thyroid C-cell tumors (boxed warning). Both drugs caused these tumors in rodents. It is not known whether this happens in humans. They are not used if you or a family member has had medullary thyroid carcinoma, or if you have MEN 2.
• Pancreatitis. Severe stomach pain that does not go away, sometimes reaching the back, needs prompt medical attention.
• Gallbladder problems. Gallstones and gallbladder inflammation have been reported.
• Kidney problems. Dehydration from vomiting or diarrhea can strain the kidneys, so fluids matter.
• Low blood sugar. The risk rises if you also use insulin or certain diabetes pills.
• Anesthesia. Tell any surgical or procedure team that you use one of these medications.

One difference stands out on the tirzepatide label. Tirzepatide can make birth control pills less effective. The Zepbound label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. If you rely on the pill, tell your provider.

How to think about the choice

Your provider looks at your full picture before recommending either program. Common factors include:

• Your goals and history. Prior experience with a GLP-1 medication, how you responded and any side effects you had.
• Tolerance. Some people feel better on one than the other. Switching is possible with provider guidance.
• Budget. Semaglutide starts at a lower monthly price. Use the plan cost tool to compare.
• Health conditions. Thyroid history, pancreatitis history, gallbladder disease, kidney function and pregnancy plans all matter.

The RULE programs use compounded medications prepared by a licensed US pharmacy for you as an individual patient. Compounded medications are not FDA-approved, which means the FDA has not reviewed them for safety, effectiveness or quality before they reach patients. That is why provider review and a licensed pharmacy are part of every RULE prescription.

Frequently asked questions

Is tirzepatide stronger than semaglutide?

In the 2025 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide. That does not mean it is the right fit for everyone. Response varies from person to person, and your provider weighs your history, tolerance and goals.

Can I switch from semaglutide to tirzepatide?

Yes, switching is possible with provider guidance. Your provider decides when to switch and what starting dose makes sense. Do not combine the two. Both brand labels say not to use them together with other GLP-1 receptor agonists.

Do I need diabetes to use either program?

No. The brand weight products are approved for adults with obesity, or adults with overweight plus at least one weight-related condition. Your provider reviews your BMI and health history during the online visit. The BMI tool gives you a quick starting point.

Which one has fewer side effects?

Their side effect profiles are very similar. Both commonly cause nausea and other digestive symptoms, especially early on and after a dose increase. Eating smaller meals, prioritizing protein and staying hydrated can help with either one.

Talk to a licensed provider

If you are deciding between semaglutide and tirzepatide, start with a secure online visit. A licensed provider will review your health history, answer your questions and decide whether a prescription is appropriate for you. If it is, a licensed US pharmacy ships your medication to your door.

This article is educational and is not medical advice. Rx programs require an online visit with a licensed provider. Results vary.